OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Vokes on Targeting HER3 in NSCLC

September 5th 2023

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

Dr Salgia on Clinical Gaps in the Development of Novel Targets in Lung Cancer

September 5th 2023

Ravi Salgia, MD, PhD, discusses clinical gaps in the development of novel targets in lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as potential strategies or steps to address these gaps in clinical practice.

Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBC

September 5th 2023

Avan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings.

Dr Li on the Evolution of HER2-Targeted Therapy in HER2+ CRC

September 5th 2023

Daneng Li, MD, discusses the evolution of treating patients with HER2-positive colorectal cancer and highlights the effects of implementing HER2-targeted therapy in this patient population.

Dr Quiroga on the Emergence of HER2-Low in Breast Cancer

September 1st 2023

Dionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.

Dr Qin on Areas of Active and Future Investigation in NSCLC

September 1st 2023

Angel Qin, MD, discusses several areas of active investigation in non–small cell lung cancer, and highlights questions necessitating future research in this disease space.

Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

September 1st 2023

Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Shah on Unmet Needs in the Treatment of Older Patients with DLBCL

September 1st 2023

Nirav N. Shah, MD, discusses the rationale for launching a phase 2 trial of split-dose R-CHOP in older patients with diffuse large B-cell lymphoma, touching on the unmet needs seen in the treatment of this population.

Dr Tauro on the Rationale for Investigating ULK3 in Multiple Myeloma

September 1st 2023

Marilena Tauro, PhD, discusses the investigation of ULK3 in patients with multiple myeloma.

Dr Islam on the Limited Use of Ibrutinib in CLL

September 1st 2023

Prioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.

Dr Goel on the Safety Profile of Tinengotinib in Solid Tumors

September 1st 2023

Sanjay Goel, MD, MS, discusses the safety profile of the TKI tinengotinib as a monotherapy and in combination with chemotherapy in patients with solid tumors.

Dr Shah on the Investigation of Split-Dose R-CHOP in DLBCL

August 31st 2023

Nirav N. Shah, MD, discusses primary outcomes from a phase 2 trial investigating split-dose R-CHOP in older patients with diffuse large B-cell lymphoma.

Dr Callahan on Commonly Used Imaging Modalities in Breast Cancer

August 31st 2023

Rena D. Callahan, MD, discusses the range of metastatic imaging techniques available in breast cancer, the benefits of liquid biopsy, and the importance of looking for bone metastases in patients with metastatic breast cancer.

Dr Fonkoua on Addressing Barriers to Cancer Clinical Trial Access

August 31st 2023

Lionel A. Kankeu Fonkoua, MD, discusses the importance of addressing barriers to clinical trial access that patients with cancer may face and increasing patient access to routine, primary care.

Dr Sokolova on the Importance of Genetic Testing in Prostate Cancer

August 31st 2023

Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.

Dr Frank on the Background of Investigating CAR22 Therapy in Relapsed/Refractory LBCL

August 31st 2023

Matthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.

Dr Gatti-Mays on Updated Biomarker Data From the NeoPACT Study in TNBC

August 31st 2023

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses updated biomarker data from the phase 2 NeoPACT trial of neoadjuvant chemoimmunotherapy in triple-negative breast cancer.

Dr Phillips on the Evaluation of Frontline Treatment With Acalabrutinib Plus BR in MCL

August 31st 2023

Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.

Dr Goel on the Mechanism of Action of Tinengotinib in Solid Tumors

August 30th 2023

Sanjay Goel, MD, MS, discusses the mechanism of action of tinengotinib and the efficacy of this agent in patients with cholangiocarcinoma.

Dr Williams on the Evolution of Treatment Approaches in Ovarian Cancer

August 30th 2023

Heather R. Williams, MD, discusses the evolution of the ovarian cancer treatment paradigm over the past several decades, as well as the importance of continuing to investigate individualized treatment approaches in this population to expand therapeutic options after disease recurrence.